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Opioid agonist treatment has been shown to reduce mortality, comorbid infections, and 
opioid cravings in patients with opioid use disorder. However, patient long-term retention on 
opioid agonist treatment is low and hindered by neurobiological and physiological changes 
caused by chronic opioid use, such as increased baseline noradrenaline and hyperalgesia. Some 
of these changes have been shown to be reversible or preventable with aerobic exercise. In this 
randomized clinical trial, we will determine whether an outpatient, adjunctive, aerobic exercise 
program designed around personal preferences can improve the retention on opioid agonist 
treatment. We will randomize 270 study subjects initiated on buprenorphine treatment to the 
exercise program and measure treatment retention at 1 year. This study will evaluate a patient-
















Chapter 1: Introduction 
1.1 Background: Opioid use disorder: Epidemiology, diagnosis, and treatment 
From 1999 to 2017, annual deaths caused by opioid overdose has risen from 8,050 to 
47,600.1 This substantial increase in deaths cements opioid overdose as the leading cause of 
unintentional deaths in the United States, leading the US Department of Health and Human 
Services to declare the opioid crisis a public health emergency in October 2017.2 Concern for 
opioid misuse extends beyond mortality, as of 2018, approximately 2 million people in the 
United States carry the diagnosis of opioid use disorder (OUD) and experience the sequelae 
associated with it.3 Like other misused substances, opioids can cause continuous craving and use 
that may often hinder one’s mental, social, and physical wellbeing. Additionally, those who use 
opioid intravenously can be exposed to skin infections that can become systemic if untreated, as 
well as significant blood borne infections including HIV, hepatitis B, and hepatitis C.4 
Financially, OUD costed the United States health system over $78 billion in treatment in 2013, 
more than other prominent chronic diseases such as asthma, stroke, and HIV infections.4 
 OUD was defined by the fifth edition of Diagnostics and Statistics Manual of Mental 
Disorders (DSM-5) in 2013 as recurrent opioid use leading to fulfillment of at least two of eleven 
criteria. These criteria range from craving of use to disruption of one’s social, occupational, and 
recreational activities. A thorough substance use questionnaire and history is critical in 
elucidating if one meets these criteria. Physical exam findings are often minimal in people who 
are not actively intoxicated or withdrawing apart from track marks in those who misuse 
intravenously.  
 With OUD’s prevalence in the United States at an all-time peak, it may seem paradoxical 
that there have been effective and safe medications available for over three decades. Methadone 
and buprenorphine are the two main medications available, with methadone being an opioid 
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agonist and buprenorphine a partial opioid agonist. As opioids, they both lead to cross-tolerance 
to other opioids and bind to mu receptors with high affinity, but with lower intrinsic activity such 
as euphoria and sedation while beneficially decreasing opioid craving and withdrawal symptoms. 
Their high mu receptor affinity blocks binding and subsequent activation of the receptor from 
exogenous opioids. Clinical trials have shown both medications to be efficacious in increasing 
social functioning, reducing illicit opioid use, decreasing mortality, as well as reducing risk of 
infections through intravenous drug use.5-7 Regulations have greatly expanded access to opioid 
agonist therapy across the United States in the past two decades.8, 9 DATA 2000 allowed 
buprenorphine to be prescribed in the clinic by physicians who have completed an 8-hour 
training course.10 Revision of the Comprehensive Addiction and Recovery Act in 2016 extended 
buprenorphine prescribing privileges to nurse practitioners and physician assistants who 
complete a similar 24 hours of training.11 Regulation in administration and prescription of both 
medications is due to their potential for misuse. Methadone can only be dispensed by certified 
opioid treatment programs and is a schedule II medication. Buprenorphine combined with 
naloxone has the added benefit of naloxone’s opioid antagonist properties when misused 
intravenously, discouraging misuse by precipitating withdrawal symptoms. Buprenorphine is 
classified as a schedule III medications due in part to this benefit, allowing it to be prescribed by 
experienced and trained providers and dispensed by pharmacies.12  
  
1.2 Statement of the Problem 
The current standard of care with opioid agonist treatment is ongoing (“maintenance”) 
therapy; it has been shown to be superior to medically supervised withdrawal (“detoxification”) 
in terms of preventing relapse.13 However, a 2018 survey showed that only about 59% of patients 
with OUD receive medication.3 A more glaring issue is that of that 59% who receive treatment, 
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only a fraction of those individuals remained in treatment. Individual clinical trials and cohort 
studies have shown buprenorphine adherence rate in the United States ranges from 40 – 60% at 
12 months with the range likely due to different definitions of adherence, different eligibility 
criteria, or induction speed of buprenorphine.14-17 Even on the high end of the retention range, 
this equates to only 35% of patients with OUD receiving and adhering to their medication 
nationally. The cause of this low percentage is multifactorial with some factors being more 
remediable than others. Disrupted sleep, hyperalgesia, psychological stress, other substance use, 
and mental health disorders are just some of the prominent factors associated with OUD and 
good predictors of poor treatment retention.18-20 Controlling or correcting these factors through 
the use of an adjunctive therapy could theoretically augment the retention rate of buprenorphine. 
Presently, there is no known adjunctive therapy with strong evidence to support its role in 
increasing retention to opioid agonist therapy.21 With roughly 38% of patients seeking treatment 
for OUD having a diagnosed psychiatric disorder, behavioral therapy is a logical adjunctive 
therapy and often recommended with opioid agonist treatment in efforts to increase treatment 
retention.7, 22 However, recent systematic reviews showed adjunctive behavioral therapy does not 
lead to a statistically significant increase in treatment retention compared to opioid agonist 
therapy alone.23, 24   
The proposed randomized controlled trial will aim to solve this gap in current treatment 
of OUD with the use of an adjunctive aerobic exercise intervention. Aerobic exercise has a well-
established efficacy in many chronic diseases such as fibromyalgia25 and hypertension.26 
Increasing evidence from observational studies to preliminary randomized controlled trials have 
pointed to its efficacy in substance use disorders such as marijuana, alcohol, and nicotine as 
well.27 However, only a single pilot study to date has explored the utility of aerobic exercise in 
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the OUD population.28 Clinical trials have shown aerobic exercise’s positive effect on disrupted 
sleep, hyperalgesia, psychological stress, other substance use, and mental health disorders, the 
same factors associated with poor buprenorphine treatment retention. Given these observations, 
the potential for aerobic exercise to increase buprenorphine treatment retention rates in the OUD 
population is certainly plausible and a possible relationship that should be explored further. 
 
1.3 Goals and Objectives 
The goal of this randomized controlled trial is to determine if a structured aerobic 
exercise intervention would significantly raise buprenorphine retention at 1 year in patients with 
OUD who are initiating treatment. 
 
1.4 Hypothesis 
 Patients with OUD initiated on buprenorphine who receive an aerobic exercise 
intervention, designed around their preferences for three one-hour sessions a week will have a 
higher rate of buprenorphine treatment retention compared to those receiving a time and 
attention control of sedentary activities over 1 year. 
 Secondary hypotheses are that patients receiving the intervention will have lower 
amounts of illicit drug and opioid use, number of opioid overdoses, number of missed 
buprenorphine doses, and an increase in quality of life measured by the Medical Outcomes Study 
Short-Form 36 Health Survey over 1 year. 
 
Hypothesis 1 (primary): 
Null hypothesis: There is no association between aerobic exercise and buprenorphine treatment 
retention in patients with OUD. 
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Alternative hypothesis: There is a positive association between aerobic exercise and 
buprenorphine treatment retention in patients with OUD. 
Hypothesis 2 (secondary): 
Null hypothesis: There is no association between aerobic exercise and number of opioid 
overdoses in patients with OUD. 
Alternative hypothesis: There is a positive association between aerobic exercise and number of 
opioid overdoses in patients with OUD. 
Hypothesis 3 (secondary): 
Null hypothesis: There is no association between aerobic exercise and illicit drug use in patients 
with OUD. 
Alternative hypothesis: There is a positive association between aerobic exercise and illicit drug 
use in patients with OUD. 
Hypothesis 4 (secondary): 
Null hypothesis: There is no association between aerobic exercise and missed buprenorphine 
doses in patients with OUD. 
Alternative hypothesis: There is a positive association between aerobic exercise and missed 
buprenorphine doses in patients with OUD. 
Hypothesis 5 (secondary): 
Null hypothesis: There is no association between aerobic exercise and quality of life in patients 
suffering from OUD. 
Alternative hypothesis: There is a positive association between aerobic exercise and quality of 
life in patients with OUD. 
 
1.5 Definitions: 
Opioid use disorder (OUD) is defined by DSM-5 as anyone having at least 2 of the following 
11 criteria in the past 12 months: 
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1. Opioids are often taken in larger amounts or over a longer period than was intended. 
2. There is a persistent desire or unsuccessful efforts to cut down or control opioid use. 
3. A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or 
recover from its effects. 
4. Craving, or a strong desire or urge to use opioids. 
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school, 
or home. 
6. Continued opioid use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of opioids. 
7. Important social, occupational, or recreational activities are given up or reduced because 
of opioid use. 
8. Recurrent opioid use in situations in which it is physically hazardous. 
9. Continued opioid use despite knowledge of having a persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by the substance. 
10. Exhibits tolerance where tolerance is defined as either a need for markedly increased 
amounts of opioids to achieve intoxication or desired effect or markedly diminished 
effect with continued use of the same amount of an opioid. 
11. Exhibits withdrawal where withdrawal is defined as either the characteristic opioid 
withdrawal syndrome or the same (or a closely related) substance is taken to relieve or 
avoid withdrawal symptoms. 
 
Severity of OUD is based on the number of criteria above met and categorized as mild (2-3), 




Aerobic Exercise is defined by the American College of Sports Medicine as any activity that 
uses large muscle groups, can be maintained continuously and is rhythmic in nature. Current 
recommendations for the healthy adult consist of 150 minutes of moderate intensity exercise per 
week. We will refer to aerobic exercise as moderate and vigorous intensity aerobic exercise, 
defined by the American College of Sports Medicine as ≥40% heart rate reserve, in the 
methodology. 
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Chapter 2: Review of Literature 
2.1 Introduction 
 A literature search through the PubMed, Scopus, and OVID Medline databases was 
conducted between July 2019 and April 2020, searching for articles related to aerobic exercise 
and buprenorphine adherence. Keywords used in the search either in combination or 
independently included aerobic exercise, exercise, physical activity, buprenorphine, methadone, 
opioid agonist therapy/treatment, opioid-related disorder, substance use, compliance, adherence, 
and treatment outcomes. Articles with abstracts pertinent to our study were identified and 
reviewed. 
 
2.2 Review of Relevant Literature 
A. Opioid Use Disorder Etiology 
 OUD is a chronic disease that commonly develops from abuse of prescription opioids or 
initial use of illicit opioids for their euphoric effect. The majority of the OUD population 
originates from prescription opioid misuse and illicit heroin misuse.1 A 2018 report showed that 
of the 9.9 million Americans who misused prescription opioids, 57.8% of them obtained the 
medication through means other than a doctor.2 A 2015 systematic review estimated that 6-8% of 
the millions of Americans prescribed opioids end up being diagnosed with OUD.3 Many of these 
individuals turn to illicit opioids such as heroin and fentanyl as a cheaper alternative to cope with 
OUD. The exact reason why certain individuals end up with OUD while others do not is still 
unclear. However, multiple studies have associated OUD with comorbid mental disorders, 
current or past use of other illicit substances, and a family history of substance misuse.4 
 Contrary to popular belief, OUD is not simply a choice made by patients, but rather an 
intricate modification of chemical signals in the brain with multiple mechanisms that lead to 
addiction among those who are exposed to illicit or prescribed opioids.5 Opioids bind to 3 
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different central nervous system transmembrane neurotransmitter receptors: mu, kappa, and 
delta. In OUD, the binding and activation of the mu receptor sets off a biochemical cascade that 
affect various parts of the brain, one of them being the mesolimbic reward system. Neurons 
activated in the ventral trigeminal area (VTA) releases dopamine to the nucleus accumbens 
(sense of pleasure) and the hippocampus (retains memory of pleasure). Chronic opioid use 
reduces the amount of dopamine release to the nucleus accumbens. This leads to what is 
colloquially called tolerance, a greater amount of opioids is needed to reproduce the same 
euphoric effects. Additionally, the amount of pleasure obtained from normally euphoric activities 
is reduced such that one is dependent on opioids to experience euphoria. The pleasurable 
memories implanted in the hippocampus cause the sense of craving, further propelling one 
towards repeated opioid use through activation of VTA glutamate neurotransmitters which 
activate the aforementioned dopamine neurons.  
Another obstacle in treating addiction is the uncomfortable withdrawal symptoms 
including diarrhea, myalgia, and anxiety that often lead to relapse. Opioids binding to mu 
receptors in the locus coeruleus (LC) suppress the LC’s ability to produce noradrenaline. 
However, LC neurons are able to adjust to the chronic suppressive effects of continuous opioid 
use and increase their baseline level of noradrenaline production to counteract the suppressive 
effect of opioids. In the event of opioid abstinence, the suppression of noradrenaline is absent 
and the excess amount of noradrenaline produces the classic opioid withdrawal symptoms. VTA 
glutamate neurotransmitters also have a role in the activation of LC neurons; opioid abstinence 
excites the neurotransmitters, stimulating noradrenaline release from LC neurons and further 




B. Potential Mechanism of Action of Aerobic Exercise  
Relapse is often cited as one of the primary non-logistical reasons for patients that 
prematurely discontinue buprenorphine treatment.6 Although buprenorphine is highly effective at 
ameliorating craving and withdrawal symptoms,7 it does not address other symptoms that the 
OUD population faces to remain abstinent.  
Opioid induced hyperalgesia is a phenomenon arising from chronic opioid use where the 
user is more sensitive to painful stimuli.8 Hyperalgesia has been observed in buprenorphine users 
in multiple studies. Athanosos et al. (2018)9 observed the pain tolerance of twelve individuals 
receiving buprenorphine compared to a control group consisting of ten participants. Pain 
tolerance was measured with the cold pressor response where participants immersed their 
nondominant arm in 0.5ºC–1.5ºC water, it was quantified as the number of seconds the 
participants took to remove their arm from the water. Individuals receiving buprenorphine were 
found to have significantly lower pain tolerance levels compared to the control group 
(ANOVA P = 0.009, 95% CI = −5 to −30). Athanosos et al. further explored if pain tolerance in 
buprenorphine users would improve with an infusion of morphine. While the control group’s 
pain tolerance increased significantly with the morphine infusion (P < 0.05, 95% CI = 2 to 34), 
there was no statistically significant differences in pain tolerance with individuals receiving 
buprenorphine after morphine infusion (P > 0.45), suggesting that an alternative therapy for 
analgesic control is needed in this population. Although this study is limited by its small sample 
size, similar findings were observed by Wachholtz and Gonzalez (2014)10 in their 120-subject 
study. The pair similarly used the cold pressor response, but quantified pain tolerance as 
sensitivity to pain (time to first experiencing pain) as well as tolerance (time to removing an arm 
from the water). The study participants were separated equally into four different groups: 
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individuals receiving methadone; individuals receiving buprenorphine; those with a history of 
opioid agonist therapy; opioid naïve control. Present and past users of opioid agonist therapy had 
no significant differences in sensitivity and tolerance between one another, but all had 
significantly increased sensitivity and decreased tolerance (28.2 and 61.4 seconds respectively) 
compared to the control group (54.4 and 137.1 seconds respectively; p<0.001). Both studies 
captured this correlation at a single point in time; it remains unclear if buprenorphine therapy is 
associated with sustained decreased pain tolerance. However, both studies still demonstrated an 
acute correlation between buprenorphine therapy and decreased pain tolerance; an adjunctive 
therapy that could increase pain tolerance in a safe and efficacious manner would benefit this 
population. 
Aerobic exercise is largely safe and potentially efficacious in inducing hypoalgesia with 
several reviews supporting its hypoalgesia effects.11, 12 Naugle et al.’s (2012)11 meta-analytic 
review consisted of eight studies that involved aerobic exercise and a measurement of pain 
tolerance. These studies measured pain tolerance in various ways including pressure, heat, and 
cold stimuli; all studies measured pain tolerance before and after a single aerobic exercise 
session ranging from ten to thirty minutes. The effect size for pain threshold was positive and 
moderate (0.48 and 0.43 when adjusted for sample size and bias). All these studies notably 
measured an acute rise in pain threshold shortly after exercise and did not assess pain threshold 
longitudinally. Comparatively, studies observing effect of chronic aerobic exercise on pain 
tolerance and sensitivity is rather limited. Jones et al. (2014)13 aimed to address this gap with 
their six-week study. Half of the 24 participants enrolled in 18 sessions of cycling for 30 minutes 
each session at 75% of HR reserve. The primary outcomes of the study were ischemic pain 
tolerance and pressure pain thresholds. At the end the study, the aerobic exercise group had a 
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significant increase in ischemic pain tolerance (t11 = −3.15, P = 0.036, +20.3%), while the 
control group was unchanged. However, there was no significant effect on pressure pain 
threshold in either the upper or lower body. (F1,22 = 0.6, P = 0.45 and F1,22 = 2.9, P = 0.1 
respectively). Other than the low sample size, this study had other notable limitations. 
Participants were not randomized and the study lacked a time and attention control, this led to 
the intervention group receiving more attention than the control group. Nonetheless, the study 
showed promising effects for sustained pain tolerance with chronic aerobic exercise. 
Sleep disturbances are another challenge that the OUD population encounters. A 2017 
cross-sectional study14 surveyed 185 patients enrolled in opioid agonist therapy on their sleeping 
habits using the Medical Outcomes Study Sleep Scale.15 Patients commonly reported not getting 
the amount of sleep they needed (42.9%), not getting enough sleep to feel rested (39.6%), 
problems falling asleep (23.3%) and falling back to sleep after awaking (25.8%). Overall, 51.3% 
of the study’s patients were classified as having impaired sleep with no significant difference 
between buprenorphine and methadone therapy. Sleep quality is poorer in nonadherent patients; 
a retrospective study by Krishnamurthy et al. (2019)16 observed that poor sleep quality is highly 
prevalent among those who dropped out of buprenorphine treatment within six months. Sleep 
quality was assessed on 70 patients using the Pittsburgh Sleep Quality Index (PSQI)17 with a 
score <5 indicating poor sleep quality; 63% of males and 80% of females scored <5. Both these 
studies are limited as they used self-reported modalities to assess for sleeping disturbances. Both 
sampled patients from an isolated region (Baltimore and central Pennsylvania respectively) 
which limits the external validity of these findings. Limitations aside, these observations suggest 




 Although there is currently no known mechanism on how aerobic exercise improves 
sleep quality exists, growing evidence suggests a strong association between the two. A 2012 
systematic review18 of six randomized clinical trials showed significant improvements in sleep 
quality measured by the PSQI (standard mean difference (SMD) of 0.47, 95% CI 0.08 to 0.86) 
with exercise. Sleep latency was notably reduced as well (SMD 0.58, 95% CI 0.08 to 1.08). Five 
of the six trials consisted of aerobic exercise, requiring participants to reach 60% of their heart 
rate reserve; duration of the trials ranged from 10 to 16 weeks. The study utilized the PEDro 
scale, a grading system assessing for areas of bias. The studies included had PEDro scale ranging 
from five to eight, indicating high internal validity.19 This strict study inclusion criteria limited 
Yang et al. to a smaller (305 participants), predominantly female sample (79%). Notably all the 
studies sampled adults over 40 years old. 
 
C. Factors Associated with Buprenorphine Nonadherence 
 Opioid agonist therapy has been repeatedly proven to be effective in OUD outcomes, 
reducing mortality, relapse, intravenous related infections, and quality of life among others.20 Its 
effectiveness is predicated on treatment adherence; patients nonadherent to buprenorphine, 
defined as taking it less than 80% of required times, are 10 times more likely to relapse to opioid 
misuse compared to adherent patients.21 Various studies have explored the predictive factors 
associated with buprenorphine nonadherence and found that many of these rectifiable factors are 
the same predictive factors for OUD (comorbid mental disorders, use of other illicit substances, 
psychosocial stability, etc.). An intervention attenuating these factors can theoretically lead to a 




C1. Comorbid Mental Disorders 
 Recent studies examining the prevalence of comorbid psychiatric disorders in the OUD 
population found it to be an estimated 38%. Litz and Leslie (2017)22 further examined the 
specific psychiatric disorders within the buprenorphine population and found anxiety (22%) and 
major depressive disorder/bipolar (15.9%) to be the most common psychiatric comorbidities 
among this subset. Although anxiety was found to be the most common psychiatric comorbidity 
in this 2947 subject sample, it was not associated with lower adherence nonadherence (defined as 
medication possession ratio ≥ 0.8) rates (odds ratio .975, CI .810 – 1.173, p = .788). However, 
with a p-value greater than 0.05 and a CI crossing 1, this was not statistically significant. Major 
depressive disorder/bipolar was found to be associated with lower adherence rates (OR .804, CI 
.651 - .994, p = .044), supporting previous literature findings of lowered medication adherence 
with a diagnosis of major depressive disorder/bipolar.23 The generalizability of this data to the 
whole population of those receiving buprenorphine is limited as this retrospective cohort study 
used the database, MarketScan, containing data only from private insurance. However, similar 
findings were observed in other studies focusing on associations of psychiatric disorders and 
buprenorphine.  
Tkacz et al. (2011)21 found a similar percentage to Litz and Leslie; 24% of their 2,197 
subject sample had a psychiatric issue. Patients nonadherent to buprenorphine had a higher 
psychiatric composite score compared to adherent patients (0.285 vs. 0.228, p = .036). 
Adherence was also defined as medication possession ratio ≥ 0.8. Psychiatric issues were notably 
assessed through the Addiction Severity Index, a self-reported assessment, and thus, prone to 
reporting bias.24 The demographics of this prospective cross-sectional study was more 
representative of the demographics of the OUD population.25 Although the demographics were 
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similar to the OUD population, this study population sought primary care, office-based 
buprenorphine treatment, which according to a 2010 report, comprised an estimated 46% of the 
buprenorphine treatment population from 2002-2009.26 Ambiguous directionality of an 
association is a common limitation in cross-sectional studies; however, the directionality of this 
study is clear. Subjects were seeking buprenorphine treatment at the time, affirming that 
psychiatric disorders lead to buprenorphine treatment. 
The association between aerobic exercise and major depressive disorder relief is well 
documented in literature with numerous meta-analytic studies supporting a positive association 
between the two variables. Morres et al.’s 201827 meta-analysis of 11 studies examined this 
association in adults and found a significant antidepressant effect with aerobic exercise (g = –
0.79, 95% CI –1.01, –0.57, P < 0.00) compared to non-exercise interventions. This meta-analysis 
differed from previous meta-analysis with its stringent eligibility criteria. Included studies 
recruited solely from mental health services as opposed to media advertisements which often 
attract patients with higher outcome expectations. This study utilized the PEDro scale and found 
most of the included studies had a PEDro scale ≥ 6, indicating high internal validity. Though 
most of the included studies had a high PEDro score, all of them lacked a time and attention 
control. Supervised aerobic intervention was compared to various interventions such as 
pharmacotherapy and psychotherapy, none of the studies accounted for the potential confounding 







C2. Comorbid Drug Use 
 Similar to psychiatric disorders, substance use other than opioids is prevalent among the 
OUD population. Cocaine, alcohol, marijuana, and benzodiazepine use have all been linked to 
lowered buprenorphine treatment retention with cocaine being the most studied of the group.  
Observational studies have found the prevalence of cocaine in people entering 
buprenorphine treatment to be an estimated 37-48.8%.28, 29 Multiple cohort studies have observed 
the negative association between baseline cocaine use and buprenorphine treatment retention. In 
a secondary analysis of a randomized clinical trial examining psychosocial counseling and 
buprenorphine retention, Sullivan et al. (2010)28 observed that baseline cocaine use in their 162 
study population led to shorter treatment retention times (mean of 15.8 vs. 18.4 weeks, p = .04) 
and lower completion rates of their 24 week treatment (33% vs. 50%, p = .04). More concerning 
of an observation was that of the 63% baseline negative cocaine group, 31% of that group were 
found to have cocaine metabolites in urine drug samples taken during the study. The treatment 
retention in the subgroup of negative baseline cocaine use, but positive cocaine use during the 
study, was also lower compared to those who were cocaine abstinent throughout (mean of 19.0 
vs. 16.5 weeks, p = .003).  
In another secondary analysis of a randomized clinical trial comparing intensive 
outpatient buprenorphine to standard outpatient treatment, Gryczynski et al. (2013)30 observed in 
their 297 study population that people entering the study with baseline cocaine use (measured 
with a urine drug sample) left treatment earlier (HR=1.71; 95% CI=1.18–2.48; p=.004) and had 
lower completion rates of their 6 month treatment (OR=2.05; 95% CI=1.25–3.35; p=.004). This 
study’s population consisted entirely of African Americans with a 61.9% male predominance, 
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contrasting well with Sullivan et al.’s 2010 study with a 76% Caucasian and 83% male 
population.  
Although literature primarily indicates cocaine use’s negative association with 
buprenorphine treatment retention, Cunningham et al. (2014)31 observed no statistical 
significance in their 87 subject prospective cohort study between cocaine use and 6 month 
buprenorphine treatment retention (AOR=1.56, 95%CI=0.58–4.17, p=0.38) when adjusting for 
age, baseline opioid analgesic use, and history of incarceration. Participants in the study were 
predominantly male (73.6%) and Hispanic (73.2%) initiated on buprenorphine in a community 
health care clinic, limiting the generalizability of their study. Unlike other studies observing the 
association between cocaine use and buprenorphine, cocaine use was not objectively measured 
through a urine drug sample. Cunningham et al. measured cocaine use through self-report, 
leaving the study susceptible to reporting bias. As evident by Sullivan et al.28, baseline negative 
cocaine users in buprenorphine treatment may initiate cocaine use during treatment leading to 
decreased buprenorphine retention rates. Cunningham et al. did not account for this occurrence, 
only measuring cocaine use at baseline, effectively assuming baseline negative cocaine users 
remained cocaine abstinence during the study.  
Although there are no current FDA approved medications for treatment of cocaine use, a 
2012 systematic review of 19 studies concluded that contingency management with cognitive 
behavioral therapy is effective at inducing cocaine abstinence.32 Though its efficacy is well 
supported, contingency management with cognitive behavioral therapy may not be ideal, 
especially in the context of concurrent buprenorphine use. Detractors of contingency 
management argue that this intervention does not alter internal motivations to change such that 
when a financial reward is withheld, patients will revert to baseline drug use. Aerobic exercise is 
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a potential treatment modality for cocaine use; multiple pre-clinical studies have observed 
reductions in cocaine use with aerobic exercise.33, 34 To date, only one randomized clinical trial 
has been done exploring this observation. De La Garza et al. (2016)35 randomized 24 patients to 
three different study conditions, running, walking, and sitting for 30 minutes, 3 times a week, for 
4 weeks. Both running and walking interventions were performed on a treadmill; the sole 
difference in these two study groups was the running group’s target heart rate was 75% of their 
maximum heart rate compared to 25% in the walking group. The sitting group served as the 
control condition and sat passively without access to sedentary leisure items throughout the 30 
minutes. De La Garza et al. observed a statistically nonsignificant reduction in cocaine use 
measured by daily urine benzoylecgonine screenings (F2,21=1.7, p=0.21). The failure to reject the 
null hypothesis may be due to the study’s low power (small sample size) and short study 
duration. Data was analyzed through the intention to treat analysis and any missing urine 
screenings were presumed to be positive, possibly contributing to a false reduction rate. Unlike 
most studies using exercise interventions, this study achieved a high (>90%) retention rate likely 
due to the use of contingency management; the completion of all 12 study sessions yielded 
participants $700. This study also interestingly observed that the walking and running groups 
produced similar reductions in cocaine use, raising the question of the intensity of aerobic 
exercise needed to reduce cocaine use. 
 
D. Association Between Aerobic Exercise and OUD 
 Currently, the only randomized controlled trial examining the utility of exercise as an 
adjunctive treatment to opioid agonist treatment (methadone) was done by Cutter et al. in 2014.36 
The study’s intervention of exercise was based on exergames on Wii Fit Plus while using a novel 
time-and-attention control of sedentary Wii games. Each patient self-reported illicit opioid and 
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cocaine use and completed questionnaires measuring psychological wellbeing before and after 
the 8-week study. Participants in both study conditions had a decrease in illicit drug use (p < 
.001, from M = 3.0 days/week to M = 1.7 days/week, d = .82), perceived stress (p = .04, d = .50), 
and an increase in optimism (p = .04, d = .50) after the study. Adherence rate was not statistically 
different between the two study conditions (p = .34, d = .36). However, the study had several 
features of note including a low exercise adherence of 62.7% in the intervention group, a low 
study size of 29 participants, and a short study duration of 8 weeks – less than the American 
College of Sports Medicine (ACSM) recommended 10 weeks minimum for research trials. The 
intervention in this study was also not a true aerobic exercise regime, patients completed 5 (2 
aerobic, 1 strength, 1 balance, and 1 yoga) exergames in an average total of 20 minutes a day, 5 
days/week. The researchers acknowledged that the exercise intervention was lacking in time 
compared to the American College of Sports Medicine minimum recommended amount of 2.5 
hours/week. Though the validity of the study’s outcomes is limited due to the aforementioned 
limitations, there are numerous takeaways to draw from. The study’s primary outcome to see if 
exergames were an acceptable (defined as perception of enjoyment, usefulness, and 
achievement) and feasible exercise intervention. Patients in the intervention group rated the 
acceptability of the intervention a 6.3 out of 7 (SD 0.9) while the control group rated the 
acceptability of their time and attention control a 6.2 out of 7 (SD 0.5). The acceptable and novel 
time and attention control should be noted for future studies, previous studies utilizing exercise 
as an intervention fail to account for the time and attention required of exercise. Though 
adherence rate to the intervention and time and attention control were similarly low at 62.7% and 




E. Review of Relevant Methodology 
E1. Selection Criteria  
 Inclusion and exclusion criteria are relatively homogenous across exercise randomized 
controlled trials in the context of substance misuse. The components of an exclusion criteria aid 
to ensure participant safety, increase intervention adherence rates, and meet a study’s primary 
end point; they typically include medical conditions that interfere with aerobic exercise.35, 36 
Individuals currently treated with opioid agonist therapy have a higher pretrial probability of 
being retained in treatment as they have already shown a propensity of being successfully 
maintained for a select amount of time37, 38 and should be excluded to avoid selection bias. 
 
E2. Intervention 
The prospect of aerobic exercise as a successful adjunctive treatment to buprenorphine is 
promising, but its efficacy may ultimately depend on the patient. Randomized clinical trials 
involving exercise as an intervention in the context of substance use are often plagued by low 
exercise adherence rates evident by the studies previously discussed, likely contributing to an 
underestimation of its benefits. Abrantes et al.’s 201139 study suggest individuals undergoing 
treatment for substance misuse are interested in engaging in an exercise program, though 47.4% 
of this study’s population consisted of patients undergoing treatment for alcohol misuse. 
Although patients desire to exercise, they may not enjoy rigid exercise protocols. A strong 
correlation between enjoyment of exercise and amount of exercise performed indicates that 





E3. Exercise Intensity 
There is a positive association between exercise intensity and health benefits41 as well as 
exercise intensity and hypoalgesia11, however, patients in Abrantes et al.’s39 study overwhelming 
preferred a moderate intensity. Additionally, higher intensity exercise has been linked to lower 
exercise adherence rates,42 though there is dispute in the literature.43 
 
E.4 Exercise Duration 
 The American College of Sports Medicine recommends a minimum of 150 minutes of 
moderate intensity exercise per week for healthy adults. Considering that most American adults 
fail to meet this criterion44, it would be unreasonable to expect someone with OUD, likely to be 
even more sedentary at baseline39, to do so. Beneficial results of exercise can still be observed in 
exercise sessions greater than 10 minutes43, especially in previously sedentary individuals. Study 
protocols would ideally aim to gradually increase exercise duration; however, researchers also 
need to be sensitive to the patient’s increasing time commitment.  
 
E.5 Additional Considerations 
 Catering to patient preferences may not be enough to overcome low exercise adherence 
rates. As previously mentioned, Cutter et al.’s36 exergame intervention was highly accepted by 
patients, yet intervention adherence rates remained low. While patients may relatively enjoy 
exercising, their lack of motivation can pose a barrier to higher adherence rates. In the previously 
mentioned 2016 De La Garza et al.41 study, the reported exercise adherence rate was 90%, 
though the study was notably a third of the length of Cutter et al.’s36 study. Their use of 
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contingency management may have contributed to this success rate; contingency management 
has had efficacious effects in the substance misuse population.45 
 
E5.1 Control 
 A control group would require an activity to avoid the confounding effects increased 
time, attention, and social interactions may have. De La Garza et al.41 did not disclose adherence 
rates to their passive sitting control group, but it would be unreasonable to expect patients to 
regularly attend such sessions for 1 year. Cutter et al.’s36 utilization of sedentary Wii games as 
their control group was well received by patients with similar adherence rates to the exergames. 
Colledge et al.46 similarly attempted to have their control group play board games, billiards, and 
paint. However, adherence was relatively poor with almost half of the group attending less than 
20% of the sessions. Patients will ultimately attend activities they enjoy and a similar approach 
in heeding to their preferences in conjunction with contingency management will be prudent in 
increasing a time and attention control’s adherence rate. 
 
E5.2 Outcomes 
 As previously mentioned though, buprenorphine’s efficacy is predicated on treatment 
adherence. Previous studies have logically operationalized buprenorphine adherence as treatment 
retention over a length of time either as a continuous or dichotomous variable. The definition of 
treatment retention in literature has predominantly revolved around attending physician visits47, 48 
or having an active prescription within a certain time of a study’s end date. When considering 
study length, OUD must be recognized as a chronic illness with wavering periods of abstinence 
and relapse. Having too short of a study length may not accurately capture the essence of this 
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phenomenon. A study length of 1 year may be ideal as literature suggests significant benefits 
associated with a year of continuous buprenorphine use including decreased opioid use and 
opioid related hospitalizations.49 Though opioid use initially decreases with buprenorphine use in 
the first two months of use, it relapses until the 1-year mark when it continuously tapers down.50 
Theoretically, guiding buprenorphine users past this time point gives them a better control of 
their illness, contributing to higher buprenorphine retention rates and ultimately, higher opioid 
abstinence rates. 
Treatment adherence may also be measured by the percentage of times a patient takes 
buprenorphine. While this would be a more direct way in measuring adherence, there is no 
objective test to measure this. Current laboratory test can detect the presence of buprenorphine 
use, measuring total buprenorphine and its metabolite, norbuprenorphine. However, 
buprenorphine dose has not been shown to correspond well with either total buprenorphine or 
norbuprenorphine in any testing modality.51 Like other medications, buprenorphine is not 
immune to diversion and this should be accounted for.52 
The fundamental goal of buprenorphine is to improve functionality through eliciting 
opioid abstinence. While it is ideal, total abstinence is a poor functional outcome as the simple 
virtue of being on buprenorphine can be effective. Many studies measure opioid abstinence 
through negative opioid urine test. Although opioid urine test can objectively measure opioid 
abstinence, it comes with limitations. Opioid drug tests can generally only detect opioids within 
3-4 days of use. Additionally, the frequency and quantity of opioid use is indiscernible. The 
Timeline Follow-Back53 instrument can complement a urine drug test and offset its limitations. 
Although it is self-reported measure, the Timeline Follow-Back instrument has been successful 
in many substance misuse studies with a high degree of validity, including opioid studies.54 OUD 
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can be a severely debilitating illness, affecting multiple dimensions of health. Multiple health 
related quality of life surveys are available that aim to quantify these dimensions. The 36-item 
short form survey (SF-36) is one such survey, measuring 8 different dimensions of health to 
calculate a global measure of health. Th SF-36’s reliability and validity are well regarded and has 
been used as a quality of life measure in many different illnesses, including OUD.55 
 
2.3 Conclusion 
 With the continued rise in the prevalence of OUD and low, unwavering buprenorphine 
retention rates, there is a need for a novel adjunctive therapy to buprenorphine. Although clinical 
trials allude to aerobic exercise’s efficacy in buprenorphine retention through hypoalgesia 
effects, sleep benefits, comorbid drug use reduction, and mental disorder reduction, the true 
relationship between the two variables remains to be established. A pilot RCT conducted by 
Cutter et al.36 showed underwhelming results, but had notable limitations. Despite these 
limitations, the study provided a strong structural template for future studies.   
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Chapter 3: Study Methods 
3.1 Study Design 
 We will conduct a single institution, multi-center, double arm, single blinded, parallel 
group, randomized controlled trial. Study subjects will include individuals with OUD entering 
opioid agonist therapy for the first time who are deemed appropriate for buprenorphine by a 
physician or midlevel provider. If they meet eligibility requirements (Figure 1) and give 
informed consent, they will undergo stratified randomization and be allocated to the intervention 
or control group.  
 The primary outcome, retention, will be measured at the end of the 1-year study as a 
dichotomous variable. Data related to secondary outcomes such as quality of life and number of 
missed buprenorphine doses will be collected at a monthly interval. To ensure patients are not 
diverting buprenorphine and are accurately self-reporting the number of missed buprenorphine 
doses, they will be required to consent to monthly drug urine measurements for buprenorphine 
metabolites throughout the study duration.  
Figure 1: Eligibility Criteria 
Inclusion 
Age ≥ 18 
Meet the DMS-5 criteria for OUD on assessment by a physician or midlevel provider 
Ability to read/understand English. 
 
Exclusion 
Current use of opioid agonist therapy 
Medical conditions or physical disabilities precluding the ability for regular aerobic exercise 
Medical condition contraindicating the use of buprenorphine  
Evidence of current suicidal or homicidal intentions 
Bulimia or anorexia  
History of seizures 
Severe untreated psychiatric disorders 







3.2 Study Population and Sampling 
 The study population will compose of adults meeting the eligibility criteria from the two 
APT Foundation locations in the greater New Haven, Connecticut area and the Adult Primary 
Care Center at Yale New Haven Hospital – Saint Raphael’s Campus over a one year time period. 
The APT Foundation is a private non-profit organization specializing in treating patients with 
substance use disorders. It serves as a large federally regulated opioid treatment program that 
dispenses methadone and prescribes buprenorphine. The Primary Center of Yale New Haven 
Hospital provides office-based buprenorphine treatment and is staffed by attending and resident 
physicians that provides addiction recovery services in addition to comprehensive medical care. 
These two organizations will provide a diverse sample population reflective of the patients with 
OUD receiving treatment in the two most common types of settings. 
It would be unethical to withhold opioid agonist therapy for an extended period as its 
mortality and morbidity benefits are overwhelmingly supported in literature. Thus, the 11 month 
recruitment period will be ongoing with weekly start dates. Individuals recruited and agreeable to 




 Eligible patients at the APT Foundation and Primary Care Center will be notified by front 
desk personnel on the details of the study. Eligible patients will also be handed a business card 
with the phone number of a presiding research assistant. Given the sequentially sensitive nature 
of the study, eligible patients will be approached right after the intake process if they are 
interested in participating to ensure they do not initiate buprenorphine until the study start date. 
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During the initial consultation session, a research assistant will elaborate on the rationale behind 
the intervention, the expectations of the study, and the time commitments required of the study. 
They will be informed of the possibility of having access to the intervention if they are to be 
randomized to the control group after conclusion of the study. Research assistants will emphasize 
that the study will not have any bearings on the requirements of either the APT Foundation or the 
Primary Care Center. Potential participants who are hesitant in agreeing to the study at that time 
may call the number provided on the business card to speak with a research assistant who will 
answer any lingering questions.  
 
3.4 Subject Protection and Confidentiality 
 Prior to the recruitment period, this study will be proposed to the Human Investigation 
Committee of the Yale School of Medicine and the APT Foundation Board to gain Institutional 
Review Board approval. The proposal will include an extensive overview of each research staff 
member involved in the study with their respective status in Human Subjects Protection training 
and Health Insurance and Portability and Accountability Act (HIPAA) training. Documents such 
as informed consent form, any financial disclosures and study questionnaires will also be 
included in the proposal. The informed consent form will detail the goals of the study, time 
requirements of the study, and potential risks and benefits of the intervention. The study will 
only recruit literate English speaking individuals, removing the need for consent forms in 
different languages; a research assistant will orally present the details of the consent form to the 
patient who will also receive a copy of the consent form. At that time, the research assistant can 
help answer any of the patient’s questions regarding the study. 
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 To maintain confidentiality, any patient medical information collected in this study will 
be stored on a secure server with added encryption software, only accessible to pertinent research 
personnel. To deidentify study participants in accordance with HIPPA, we will use the Safe 
Harbor method which removes 18 identifiers such as name, phone number, and social security 
number and assigns a unique ID number which becomes attached to all the patient’s study data. 
Paper files used in the study will be transferred onto the secure server and subsequently 
shredded. 
 
3.5 Study Variables and Measures 
A. Interventions 
 The intervention group will receive a yearlong aerobic exercise regime with the primary 
intent of increasing buprenorphine adherence while the control group will undergo a time and 
attention control.  Patients in the intervention group will attend three one-hour sessions per week 
at Yale New Haven Health’s Livingwell Fitness Center. Multiple sessions a week will be 
scheduled to account for patient schedule flexibility and transportation will be provided. Given 
the study’s estimated sample size, sessions will be capped at 20 participants to allow for 
adequate room. Sessions will be led by an exercise physiologist and conducted in groups with 
two parallel sessions to account for different fitness levels; participants have the option to pick 
which session to attend prior to every session. A session will be composed of a 5 minute 
warmup, 40 minute conditioning, 5 minute cooldown, and 10 minute stretching phase in that 
order. Warmup, cooldown and stretching phases aim to ensure musculoskeletal longevity 






 To control for the time and attention of the intervention group, the control group will 
attend three one-hour sessions per week as well and engage in a sedentary activity. The control 
group’s logistics will be identical to the intervention groups. A parallel session will still be held 
to give a wider range of activities in efforts to increase control adherence and for the logistical 
purpose of having the physical space to accommodate participants. Sessions will be led by 
activity coordinators and held in vacant Yale University buildings. 
 
C. Standard Medication Management Care 
 Both study groups will continue to receive patient specific buprenorphine treatment 
throughout the duration of this study. The initial intake process in both the APT Foundation and 
the Primary Care Center at Yale New Haven Hospital involves a thorough psychosocial history 
performed by a clinician to evaluate if buprenorphine is appropriate for the patient. Patient 
specific adjunctive therapy at these sites accompanies buprenorphine induction; therapy may 
include a mixture of cognitive based therapy, motivational interviewing, 12-step counseling, etc. 
Buprenorphine will be offered as Suboxone, a sublingual film form that includes buprenorphine 
and naloxone as its active ingredients in a 4:1 ratio. Induction of buprenorphine and subsequent 
treatment doses will be based on the American Society of Addiction Medicine guidelines.2 
During monthly follow-up meetings with the respective clinic, urine will be collected to evaluate 
drug misuse and buprenorphine adherence. In both groups, individuals will be told to refrain 






D. Baseline Variables 
 Baseline demographics and clinical characteristics of both study groups will be 
compared. Such characteristics include age, sex, race, body-mass index, employment status, 
education level, illicit drug use, counseling hours, buprenorphine maintenance dose, major 
depressive disorder diagnosis and length of opioid use (Table 1). 
Table 1: Baseline Patient Characteristics 
 
E. Primary and Secondary Outcomes 
 The primary outcome variable in this study will be the percentage of patients retained on 
buprenorphine treatment at 1 year. To be considered retained, participants must have been 
continuously in treatment and test positive for urine buprenorphine metabolites at the end of the 
year study. We will define continuous treatment as participants having an active buprenorphine 
prescription within 45 days and have communicated with the clinic within 45 days.3 
Buprenorphine is typically prescribed as a monthly take home medication in stabilized patients, 
the extra 15 day grace period is to account for unforeseen circumstances (e.g. loss of insurance). 
Participants who fail to meet either of those criteria will be considered as not retained. Those lost 
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to follow up who desire to return to the study will be allowed if start dates remain. However, 
they will be considered as a new participant, time accrued before being lost to follow up will be 
nulled. 
 Secondary outcome variables include: 
o Number of opioid overdoses 
▪ The number of opioid overdoses will be a self-reported number. 
Additionally, research assistants will check patients’ electronic medical 
records for any hospital visits concerning overdoses. 
o Amount of illicit drug and opioid use 
▪ The amount of illicit drug and opioid use will be measured by a monthly 
Timeline Follow-back questionnaire. Substances of interest will include 
heroin, cocaine, alcohol, marijuana, and illicit opioids. Each participant 
will be asked to provide monthly total urine samples to verify these self-
reported numbers. Temperature strips will be used as one measure to 
ensure urine samples are not adulterated or substituted. 
o Number of missed buprenorphine doses 
▪ The number of missed buprenorphine doses will be a self-reported 
number. To ensure patients are not diverting buprenorphine and are 
accurately self-reporting the number of missed buprenorphine doses, 
monthly urine sample testing for buprenorphine and its metabolite, 
norbuprenorphine, will be collected. Patients with a buprenorphine level ≥ 
700ngmL4 or a buprenorphine:norbuprenorphine ratio ≥ 0.25 will be 
considered as nonadherent.  
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o Quality of life 
▪ This will be measured by the Medical Outcomes Study Short-Form 36 
Health Survey. This 36-question survey asks questions pertaining to one’s 
physical and mental wellbeing with some questions being weighted more 
than others. 











     
Male 
     
Female 
     
Age 
     
<20 
     
21-30 
     
31-40 
     
41-50 
     
51-60 
     
61-70 
     
>70 
     
Race 
     
White 
     
Black 
     
Hispanic 
     
Asian 
     
Other 
     
BMI 
     
<18.5 
     
18.5-25 
     
25-30 
     
>30 
     
Employed 
     
Yes 
     
No 
     
Graduated High School 
     
Yes 
     
No 
     
Current Cocaine Use 
     
Yes 




     
Major Depressive Disorder 
     
Yes 
     
No 
     
Buprenorphine Maintenance Dose 
     
4mg 
     
8mg 
     
12mg 
     
16mg 
     
20mg 
     
24mg 
     
Length of Opioid Use 
     
<12 months 
     
13-24 months 
     
24-36 months 
     
>36 months 
     
 
 
3.6 Methodological Considerations 
A. Assignment of Intervention 
 Enrolled patients will undergo stratified randomization through a computer to allocate a 
1:1 intervention to control group ratio. Patients will be stratified on gender and race, two 
potential confounding variables observed in the literature. Gender will be a dichotomous stratum, 
either male or female; race will be a nominal stratum, grouped as White, Black, Hispanic, Asian 
and other. These classifications will be based on what is stated on electronic medical records. A 
single research assistant’s sole role will be to oversee randomization at all sites. After the 
randomization, the research assistant will communicate each patient’s study allocation to the 
onsite research assistants who will deliver sealed, opaque envelopes with a patient’s study 
allocation to the respective patient. 
 
 
B. Blinding of Intervention 
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 Due to the nature of this study, blinding of the intervention to the study groups is not 
possible. However, clinical staff at the APT Foundation and Adult Primary Care Center will be 
blinded of the patient’s study allocation. Patients in both study groups will be explicitly told not 
to disclose their group study allocation with their clinical team.  
 
C. Blinding of Outcome 
 Research assistants administering surveys throughout the study measuring secondary 
outcomes will be unaware of patient’s study allocation. The research assistants involved with the 
assignment of intervention and the clinical staff at APT Foundation and Adult Primary Care 
Center will not be involved in assessing study outcomes. 
 
D. Intervention Adherence 
 Patient attendance to assigned treatment arm will be recorded prior to the start of every 
session by the session leader; treatment adherence will be defined as attending a minimum of 
80% of required sessions (124 out of 156 sessions). In efforts to increase adherence to the 
exercise intervention, a monthly survey with a list of aerobic exercises will be given to patients, 
allowing patients in effect, to vote for their specific type of intervention and continuously tailor 
activities to their preferences. Popular aerobic exercise types determined by the survey will be 
used as the intervention every week until the next survey results. The same procedure will be 
done for the control arm. After survey results are finalized, a monthly calendar will be 
distributed with a schedule of classes, ensuring patients are informed of activities and start times. 
Classes will be held in the morning and evening to accommodate patient obligations (work, 
childcare, etc.). Travel expenses will be reimbursed weekly to mitigate intervention 
nonadherence due to inaccessibility. To further encourage intervention adherence, patients will 
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be compensated $15 for attendance and weekly raffles for $150 will be held. A raffle ticket is 
earned by attending a session, bonus tickets are rewarded for attending consecutive sessions (e.g. 
attending all 3 required sessions in a week will grant an additional ticket).  
 As we are defining aerobic exercise as moderate intensity aerobic exercise, we will use 
Polar M200 watches to measure heart rate during exercise sessions. Maximal heart rate will be 
estimated using the Gellish equation: HRMax = 207 – (0.7 x age).
6 Patients who fail to reach the 
≥40% heart rate reserve threshold in the conditioning phase of the session will be notified and 
considered as if they were absent for the session. The Polar M200 is also capable of logging 
heart rate measurements which can be reviewed when the watch is connected to a computer. 
Patients who have sustained heart rate reserves >40% for ≥150 minutes per week outside of the 
intervention will be considered as nonadherent to study protocols. This exercise restriction 
outside allocated study time will be incentivized in both study arms with the benefit of keeping 
the watch after conclusion of the study for adherent patients.  
 Participants will be required to inform the research team if unanticipated events arise that 
preclude buprenorphine use or attendance to activity sessions. In addition, research assistants 
will check the National Death Index on a monthly basis in attempt to account for patients lost to 
follow up. 
 
3.7 Data Collection 
 Primary and secondary outcomes will be collected within the 1-year study length. The 
primary outcome of retention will be measured at the end of the patient’s study duration. One of 
the secondary outcomes, quality of life, will be measured during intake and again at the 
conclusion of the study. Other secondary outcomes which include number of overdoses, number 
of missed buprenorphine doses, and amount of illicit drug and opioid use will be measured 
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monthly. Research assistants will oversee administering questionnaires and surveys related to 
secondary outcomes and transfer data results over to the dedicated secure server. Baseline patient 
characteristics will hinge on those collected during the intake process by site clinicians 
 
3.8 Sample Size Calculation 
 This study’s design entails two-sided hypothesis testing, an alpha of 5% and power of 
80%. Using 49.45% as the current 1-year buprenorphine treatment retention rate, to detect an 
effect size of more than a 17.55% increase in percentage of participants in the intervention group 
retained in treatment at 1 year, a total sample size of 270 participants will be needed given an 
enrollment ratio of 1. The current 1-year buprenorphine retention rate is based off the average 1-
year retention rate observed in 2 relatively recent studies done in urban cities with similar 
demographics and definition of retention to the one proposed by this study.3, 7 Effect size was 
measured by the difference between the current 1-year buprenorphine treatment retention rate 
and that of the 1-year buprenorphine treatment retention rate of Boston Medical Center's Office 
Based Addiction Treatment Program (67%). The program reports one of the highest retention 
rates in a Northeast urban city, innovatively using nurse care managers to aid in buprenorphine 
treatment delivery.8 An attrition rate of 10% is accounted for in this sample size calculation 




3.9 Statistical Analysis 
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Baseline patient characteristics will be compared between the two study arms using chi 
square test for proportions of categorical variables and independent t-test for normally distributed 
continuous variables (Table 1).  
The primary outcome of retention will be evaluated with a chi square test. If baseline 
characteristics prove to be unequal even after randomization, retention will be evaluated with a 
multivariate regression instead. Secondary outcomes including the amount of illicit drug and 
opioid use and number of missed buprenorphine doses will be evaluated with independent t-tests. 
Quality of life will be measured with a paired t-test.  
 Statistical analysis will follow an intention to treat analysis with statistical significance 
defined as p < 0.05. 
 
3.10 Timeline and Resources 
The study will begin its 11 month rolling basis recruitment on January 4, 2021. Each 
patient is expected to be in the study for a year. Patients lost to follow up who wish to reenroll in 
the study may do so only within the recruitment period. The study will conclude in 2 years on 
January 4, 2023 with data collection and statistical analysis completed within the time frame.  
Personnel required in this study include 5 research assistants, 4 certified strength and 
conditioning specialist and 4 activity coordinators. Each of the three clinical sites will have its 
own exclusive research assistant. One research assistant will oversee the randomization process 
while another oversees administration of questionnaires and surveys.  
Essential locations include Yale New Haven Health’s Livingwell Fitness Center and Yale 
University classrooms. We will request access to these areas for the purposes of this study prior 
to the study’s start date. 
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Chapter 4: Conclusion 
4.1 Strengths and Advantages 
 Our proposed study will be the first of its kind to explore the efficacy of aerobic exercise 
in buprenorphine retention. Other than its novelty, the primary strength of our study lies in the 
design of our intervention in accordance with American College of Sports Medicine guidelines 
and the use of a time and attention control. Its flexible and preferential structure in addition to the 
use of contingency management aims to ensure adequate intervention and control adherence 
rates. Additionally, our study’s methodology promotes internal validity. Stratified randomization 
and allocation concealment will limit selection bias and ensure similar baseline characteristics in 
potential confounding variables. Blinding of clinicians and interviewers will prevent detection 
and observer bias.  
 A multi-center approach provides a large population to draw from; previous studies 
involving exercise and substance use are often limited by a low sample size. The use of a private 
organization and a major teaching hospital will give us access to a diverse patient population.  
 
4.2 Limitations and Disadvantages 
 Although our study design minimizes selection bias, the very nature of the intervention 
leads to unavoidable areas of bias. As enrollment is voluntary, many patients who choose to 
enroll already have a predilection towards aerobic exercise. This limits external validity and 
given that blinding patients is impossible, introduces bias into the study as patients may have a 
favorable belief of aerobic exercise. We are likely to lose patients who are randomized to the 
control arm due to the desire to exercise. Even though we will be offering the intervention to 
these patients after completion of the study, we acknowledge the additional time commitment it 
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would entail. Furthermore, studies who have high exercise adherence rates with the utilization of 
contingency management were relatively short in duration. It remains unestablished how 
adherent patients will be in a year long study and it would be reasonable to expect some levels of 
nonadherence in both study arms. The financial cost of contingency management over a full year 
will be significant in addition to the salaries of the study staff. Finally, although the Polar M200 
watch can theoretically monitor aerobic exercise outside of the allocated study time, patients may 
still find ways to exercise undetected, such as having another person wear the watch for them. 
 It should also be acknowledged that patients leave buprenorphine treatment for reasons 
other than relapse. Such reasons include disagreements with a treatment program’s structure and 
involuntary discharge due to financial restrictions, incarceration, and failing to meet program 
obligations.1 These are all aspects that contribute to buprenorphine’s low retention rate and areas 
that aerobic exercise cannot rectify.  
 
4.3 Clinical and Public Health Significance 
 OUD remains a major public health emergency associated with severe morbidity and 
mortality. However, the battle against the opioid epidemic has gained significant traction in the 
past few years with political involvement and increased funding. Most recent surveyed data by 
SAMSHA shows the total number of patients with OUD decreased from 2.1 to 2 million people 
between 2017 and 20182 and more people were treated with opioid agonist therapy. Although 
this is a step in the right direction, we must recognize the gaps in the current standard of care to 
further progress in this endeavor. Buprenorphine is a safe and effective drug for OUD with low 
retention rates. Aerobic exercise has been shown in theory to alleviate this issue. This study 
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seeks to explore its efficacy in practice and if successful, change the way clinicians approach 
OUD. 
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Name:____________________ Ref. Dr:___________________ Date: _______ 
ID#: _______________ Age: _______ Gender: M / F 
Please answer the 36 questions of the Health Survey completely, honestly, and without interruptions.  
GENERAL HEALTH: 
In general, would you say your health is: 
 Excellent Very Good Good Fair Poor 
Compared to one year ago, how would you rate your health in general now? 
 Much better now than one year ago 
Somewhat better now than one year ago 
About the same 
Somewhat worse now than one year ago Much 
worse than one year ago 
LIMITATIONS OF ACTIVITIES: 
The following items are about activities you might do during a typical day. Does your health now limit you in these activities? 
If so, how much? 
Vigorous activities, such as running, lifting heavy objects, participating in strenuous sports. 
Yes, Limited a lot Yes, Limited a Little No, Not Limited at all 
Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf 
Yes, Limited a Lot 
Lifting or carrying groceries 
Yes, Limited a Little No, Not Limited at all 
Yes, Limited a Lot Yes, Limited a Little No, Not Limited at all 
Climbing several flights of stairs 
Yes, Limited a Lot Yes, Limited a Little No, Not Limited at all 
Climbing one flight of stairs 
Yes, Limited a Lot Yes, Limited a Little No, Not Limited at all 
Bending, kneeling, or stooping 
Yes, Limited a Lot Yes, Limited a Little No, Not Limited at all 
Walking more than a mile 
Yes, Limited a Lot Yes, Limited a Little No, Not Limited at all 
Walking several blocks 










Bathing or dressing yourself 
Yes, Limited a Lot Yes, Limited a Little  
PHYSICAL HEALTH PROBLEMS: 
No, Not Limited at all 
During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a 
result of your physical health? 
Cut down the amount of time you spent on work or other activities 
Yes No 
Accomplished less than you would like 
Yes No 
Were limited in the kind of work or other activities 
Yes No 
Had difficulty performing the work or other activities (for example, it took extra effort) 
Yes No 
EMOTIONAL HEALTH PROBLEMS: 
During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a 
result of any emotional problems (such as feeling depressed or anxious)?  
Cut down the amount of time you spent on work or other activities 
Yes No 
Accomplished less than you would like 
Yes No 
Didn't do work or other activities as carefully as usual 
Yes No 
SOCIAL ACTIVITIES: 
Emotional problems interfered with your normal social activities with family, friends, neighbors, or groups? 
Not at all Slightly Moderately Severe Very Severe 
PAIN: 
How much bodily pain have you had during the past 4 weeks? 
None Very Mild Mild Moderate Severe Very Severe 
During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the 
home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely 













These questions are about how you feel and how things have been with you during the last 4 weeks. For each question, 
please give the answer that comes closest to the way you have been feeling.  
Did you feel full of pep? 
All of the time 
Most of the time 
A good Bit of the Time 
Some of the time 
A little bit of the time 
None of the Time 
Have you been a very nervous person? 
All of the time 
Most of the time 
A good Bit of the Time 
Some of the time 
A little bit of the time 
None of the Time 
Have you felt so down in the dumps that nothing could cheer you up? 
All of the time 
Most of the time 
A good Bit of the Time 
Some of the time 
A little bit of the time 
None of the Time 
Have you felt calm and peaceful? 
All of the time 
Most of the time 
A good Bit of the Time 
Some of the time 
A little bit of the time 
None of the Time 
Did you have a lot of energy? 
All of the time 
Most of the time 
A good Bit of the Time 
Some of the time 
















Have you felt downhearted 
and blue? 
All of the time 
Most of the time 
A good Bit of the Time 
Some of the time 
A little bit of the time 
None of the Time 
Did you feel worn out? 
All of the time 
Most of the time 
A good Bit of the Time 
Some of the time 
A little bit of the time 
None of the Time 
Have you been a happy person? 
All of the time 
Most of the time 
A good Bit of the Time 
Some of the time 
A little bit of the time 
None of the Time 
Did you feel 
tired? All of the 
time 
Most of the time 
A good Bit of the Time 
Some of the time 
A little bit of the time 
None of the Time 
SOCIAL ACTIVITIES: 
During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with 






























All of the time 
Most of the time 
Some of the time 
A little bit of the time 
None of the Time 
GENERAL HEALTH: 
How true or false is each of the following statements for you? 
I seem to get sick a little easier than other people 
Definitely true Mostly true Don't know Mostly false Definitely false 
I am as healthy as anybody I know    
Definitely true Mostly true 
I expect my health to get worse 
Don't know Mostly false Definitely false 
Definitely true Mostly true 
My health is excellent 
Don't know Mostly false Definitely false 




    Appendix C: Consent Form 
                                              
 
Hi, my name is Timothy Fong and I am a Physician Associate student from Yale School of 
Medicine. I am conducting a research study to examine the effect of aerobic exercise on 
buprenorphine adherence. Participation in this study will involve either partaking in group 
aerobic exercise classes or group sedentary activities. Your involvement will require 3 hours a 
week for one year. You will receive $15 per session you attend with the chance to participate in 
weekly raffles for additional monetary prizes.  
 
You may experience musculoskeletal injuries and in rare cases, arrythmias, sudden cardiac 
arrest, and myocardial infarctions. We hope this study will support you through your opioid use 
disorder by improving your general wellbeing. We hope that our results will add to the 
knowledge about the effects of aerobic exercise has on buprenorphine adherence.  
 
All of your responses will be held anonymous. Only the researchers involved in this study and 
those responsible for research oversight will have access to the information you provide.  Your 
responses will be handwritten or performed over the computer.  
 
Your responses will be linked to a unique ID number and stored on a secure server with added 
encryption software. Any study results written on paper will be shredded after being transferred 
to the server. The information you provide will eventually be destroyed after publication of the 
study.  
 
Participation in this study is completely voluntary. You are free to decline to participate, to end 
participation at any time for any reason. Your decision whether or not to participate in this study 
will not affect your relationship with the APT Foundation, Adult Primary Care Center, or Yale 
School of Medicine.  
 
If you have any questions about this study, you may contact the investigator, Timothy Fong at 




If you would like to talk with someone other than the researchers to discuss problems or 
concerns, to discuss situations in the event that a member of the research team is not available, 
or to discuss your rights as a research participant, you may contact the Yale University Human 
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